News

ascopubs.org2d
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor ...
In the uptitration arm (n = 50), confirmed ORR was 16.0% (95% CI, 7.2 to 29.1) and PFS was 6.7 (95% CI, 4.2 to 8.8) months. An analysis of intracranial response was performed in 30 patients from the ...